MX338436B - Preparacion liofilizada de toxinas de botulismo. - Google Patents
Preparacion liofilizada de toxinas de botulismo.Info
- Publication number
- MX338436B MX338436B MX2013011119A MX2013011119A MX338436B MX 338436 B MX338436 B MX 338436B MX 2013011119 A MX2013011119 A MX 2013011119A MX 2013011119 A MX2013011119 A MX 2013011119A MX 338436 B MX338436 B MX 338436B
- Authority
- MX
- Mexico
- Prior art keywords
- botulinum toxin
- lyophilized preparation
- present
- transportation
- animal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a un preparado farmacéutico liofilizado que contiene: -toxina botulínica, polisorbato y metionina; y -uno o más componentes seleccionados del grupo de los azucares, de los alcoholes de azúcar y de los compuestos jónicos, donde el preparado está libre de albúmina. El preparado farmacéutico liofilizado en donde la toxina botulínica se selecciona del grupo formado por Serotipos de Toxina A, B, C, D, E, F, y G.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20110029577 | 2011-03-31 | ||
PCT/KR2012/002418 WO2012134240A2 (ko) | 2011-03-31 | 2012-03-30 | 보툴리눔 독소의 동결건조제제 |
KR1020120033374A KR101395064B1 (ko) | 2011-03-31 | 2012-03-30 | 보톨리눔 독소의 동결건조제제 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013011119A MX2013011119A (es) | 2014-02-27 |
MX338436B true MX338436B (es) | 2016-04-18 |
Family
ID=47282510
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013011119A MX338436B (es) | 2011-03-31 | 2012-03-30 | Preparacion liofilizada de toxinas de botulismo. |
MX2016004606A MX355771B (es) | 2011-03-31 | 2012-03-30 | Preparacion liofilizada de toxinas de botulismo. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016004606A MX355771B (es) | 2011-03-31 | 2012-03-30 | Preparacion liofilizada de toxinas de botulismo. |
Country Status (22)
Country | Link |
---|---|
US (3) | US8920795B2 (es) |
EP (3) | EP2692350B2 (es) |
JP (3) | JP5826914B2 (es) |
KR (1) | KR101395064B1 (es) |
CN (2) | CN109925284A (es) |
AU (2) | AU2012233845B2 (es) |
BR (1) | BR112013025256B1 (es) |
CA (1) | CA2831908C (es) |
CO (1) | CO6821888A2 (es) |
DK (2) | DK3241547T3 (es) |
ES (2) | ES2636680T5 (es) |
HK (1) | HK1246174A1 (es) |
HU (1) | HUE050037T2 (es) |
IL (1) | IL228607B (es) |
MX (2) | MX338436B (es) |
PL (2) | PL3241547T3 (es) |
PT (1) | PT3241547T (es) |
RU (2) | RU2640922C1 (es) |
SG (3) | SG10201605324PA (es) |
SI (1) | SI3241547T1 (es) |
WO (1) | WO2012134240A2 (es) |
ZA (1) | ZA201308115B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2578250C (en) * | 2004-07-26 | 2013-03-05 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition with a botulinum neurotoxin |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
EP2170400B1 (en) * | 2007-07-10 | 2012-07-25 | Medy-Tox, INC. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
KR102005930B1 (ko) | 2008-12-31 | 2019-07-31 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
CN102869373B (zh) * | 2009-06-25 | 2017-05-10 | 雷文斯治疗公司 | 不含白蛋白的肉毒杆菌毒素制剂 |
CN109925284A (zh) * | 2011-03-31 | 2019-06-25 | 株式会社美得拓石 | 肉毒杆菌毒素冻干制剂 |
US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
EP3188706B1 (en) | 2014-09-02 | 2019-10-09 | American Silver, LLC | Botulinum toxin and colloidal silver particles |
JP6781508B2 (ja) * | 2014-11-18 | 2020-11-04 | 塩野義製薬株式会社 | 安定化されたペプチド組成物 |
KR101737387B1 (ko) | 2015-06-01 | 2017-05-18 | 유용우 | 2차 발효 홍삼을 이용한 건강기능식품의 제조방법 |
AU2017227978B2 (en) * | 2016-03-02 | 2022-03-10 | Merz Pharma Gmbh & Co. Kgaa | Composition comprising botulinum toxin |
HRP20191966T4 (hr) | 2016-09-13 | 2022-09-16 | Allergan, Inc. | Stabilizirani neproteinski klostridijalni pripravci toksina |
KR101744900B1 (ko) | 2017-01-20 | 2017-06-08 | 주식회사 대웅 | 보툴리눔 독소를 포함하는 안정한 액상 조성물 |
CN107540732B (zh) * | 2017-08-31 | 2020-07-14 | 青海省畜牧兽医科学院 | 一种d型肉毒毒素的仿生矿化加工方法及应用 |
KR101968873B1 (ko) * | 2018-09-21 | 2019-04-29 | 아이큐어 주식회사 | 세포 침투 효과가 우수한 보툴리늄 유래 펩타이드를 포함하는 화장료 조성물 |
KR102259423B1 (ko) * | 2018-11-30 | 2021-06-02 | 주식회사 휴온스바이오파마 | 보툴리눔 독소의 안정화 액상 조성물 |
WO2020111852A1 (ko) * | 2018-11-30 | 2020-06-04 | 주식회사 휴온스글로벌 | 보툴리눔 독소의 안정화 액상 조성물 |
CN113573727A (zh) | 2019-02-21 | 2021-10-29 | 梅尔兹制药公司 | 肉毒神经毒素用于治疗震颤的新用途 |
CN110637814B (zh) * | 2019-10-22 | 2021-11-19 | 青海省畜牧兽医科学院 | 一种d型肉毒毒素的微囊化制备方法 |
WO2021086123A1 (ko) * | 2019-10-31 | 2021-05-06 | 휴젤㈜ | 보툴리눔 독소에 대한 마이크로 구조체 제형화 기술 |
EP4186520A4 (en) | 2020-07-23 | 2024-05-01 | Medytox Inc. | THERAPEUTIC AGENT AGAINST CANCER |
KR102414997B1 (ko) * | 2020-09-29 | 2022-06-29 | 주식회사 엘지생활건강 | 안정성이 개선된 재조합 보툴리눔 독소 경쇄 단백질 조성물 |
KR20220114183A (ko) * | 2021-02-08 | 2022-08-17 | 주식회사 대웅 | 장기 저장이 가능한 보툴리눔 독소 동결건조 제형 조성물 |
KR20230001254A (ko) | 2021-06-28 | 2023-01-04 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
KR20230001260A (ko) | 2021-06-28 | 2023-01-04 | (주)메디톡스 | 재조합 보툴리눔 독소 타입 a 경쇄, 재조합 보툴리눔 독소 및 이의 조성물, 용도 및 방법 |
KR102427362B1 (ko) | 2021-11-11 | 2022-08-01 | (주)이니바이오 | 보툴리눔 독소 제제의 건조 공정 |
WO2023085849A1 (ko) * | 2021-11-15 | 2023-05-19 | (주)메디톡스 | 보툴리눔 독소 조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5756468A (en) * | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
US20030118598A1 (en) † | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
DE60125986T3 (de) | 2000-02-08 | 2011-07-28 | Allergan, Inc., 92612, Calif. | Pharmazeutische Zusammensetzungen mit Botulinum Toxin |
DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
CN101175478A (zh) * | 2005-10-06 | 2008-05-07 | 阿勒根公司 | 非蛋白稳定的梭菌毒素药物组合物 |
MX2009012570A (es) * | 2007-06-01 | 2010-03-15 | Merz Pharma Gmbh & Co Kgaa | Proceso para proveer un relajante muscular estable a la temperatura a base del componente neurotoxico de la toxina botulinica en forma solida. |
EP2170400B1 (en) * | 2007-07-10 | 2012-07-25 | Medy-Tox, INC. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
EP2373294B1 (en) * | 2008-12-10 | 2016-04-20 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
KR101135449B1 (ko) * | 2009-03-10 | 2012-04-13 | 한국과학기술연구원 | 헤파라나제 활성 측정용 이온 복합체 나노 입자 및 그 제조방법 |
EP2248518B1 (en) † | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
CN109925284A (zh) * | 2011-03-31 | 2019-06-25 | 株式会社美得拓石 | 肉毒杆菌毒素冻干制剂 |
US8420106B1 (en) * | 2012-03-12 | 2013-04-16 | William J. Binder | Extramuscular treatment of traumatic-induced migraine headache |
-
2012
- 2012-03-30 CN CN201910264812.XA patent/CN109925284A/zh active Pending
- 2012-03-30 BR BR112013025256-1A patent/BR112013025256B1/pt active IP Right Grant
- 2012-03-30 PL PL17168989T patent/PL3241547T3/pl unknown
- 2012-03-30 EP EP12765216.2A patent/EP2692350B2/en active Active
- 2012-03-30 SG SG10201605324PA patent/SG10201605324PA/en unknown
- 2012-03-30 CN CN201280016784.6A patent/CN103596580A/zh active Pending
- 2012-03-30 MX MX2013011119A patent/MX338436B/es active IP Right Grant
- 2012-03-30 SG SG10202013124XA patent/SG10202013124XA/en unknown
- 2012-03-30 RU RU2015150422A patent/RU2640922C1/ru active
- 2012-03-30 ES ES12765216T patent/ES2636680T5/es active Active
- 2012-03-30 AU AU2012233845A patent/AU2012233845B2/en active Active
- 2012-03-30 DK DK17168989.6T patent/DK3241547T3/da active
- 2012-03-30 PT PT171689896T patent/PT3241547T/pt unknown
- 2012-03-30 KR KR1020120033374A patent/KR101395064B1/ko active IP Right Grant
- 2012-03-30 SI SI201231811T patent/SI3241547T1/sl unknown
- 2012-03-30 WO PCT/KR2012/002418 patent/WO2012134240A2/ko active Application Filing
- 2012-03-30 PL PL12765216.2T patent/PL2692350T5/pl unknown
- 2012-03-30 JP JP2014502485A patent/JP5826914B2/ja active Active
- 2012-03-30 DK DK12765216.2T patent/DK2692350T4/da active
- 2012-03-30 HU HUE17168989A patent/HUE050037T2/hu unknown
- 2012-03-30 CA CA2831908A patent/CA2831908C/en active Active
- 2012-03-30 RU RU2013148119/15A patent/RU2574011C2/ru active
- 2012-03-30 US US14/008,326 patent/US8920795B2/en active Active
- 2012-03-30 ES ES17168989T patent/ES2810098T3/es active Active
- 2012-03-30 MX MX2016004606A patent/MX355771B/es unknown
- 2012-03-30 EP EP17168989.6A patent/EP3241547B1/en active Active
- 2012-03-30 SG SG2013073622A patent/SG194039A1/en unknown
- 2012-03-30 EP EP20172705.4A patent/EP3756656A1/en active Pending
-
2013
- 2013-09-29 IL IL228607A patent/IL228607B/en active IP Right Grant
- 2013-10-29 CO CO13256647A patent/CO6821888A2/es not_active Application Discontinuation
- 2013-10-30 ZA ZA2013/08115A patent/ZA201308115B/en unknown
-
2014
- 2014-11-05 US US14/533,735 patent/US9198958B2/en active Active
-
2015
- 2015-10-14 JP JP2015202730A patent/JP6005239B2/ja active Active
- 2015-11-30 US US14/954,261 patent/US20160089442A1/en not_active Abandoned
-
2016
- 2016-02-19 AU AU2016201040A patent/AU2016201040B2/en active Active
- 2016-09-06 JP JP2016173874A patent/JP6173547B2/ja active Active
-
2018
- 2018-05-03 HK HK18105697.5A patent/HK1246174A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX355771B (es) | Preparacion liofilizada de toxinas de botulismo. | |
MX2021004479A (es) | Agentes biologicos y su uso en plantas. | |
MX2016000719A (es) | Composiciones y metodos que comprenden una variante de enzima lipolitica. | |
EP2802652A4 (en) | CLOSTRIDIUM HISTOLYTICUM ENZYME AND METHOD FOR USE THEREOF | |
EP2818543A4 (en) | BACILLUS, HYALURONIC ACID ZYM AND USES THEREOF | |
MX340172B (es) | Formulaciones estables de una enzima degradadora de hialuronano. | |
MX2015003874A (es) | Modulacion de ire1. | |
UY34332A (es) | Composiciones y métodos para controlar malezas co mprendiendo un polinucleótido y agente de transfe rencia, y que modulan la fitoeno desaturasa?. | |
WO2013154657A3 (en) | Turbine blade damper seal | |
WO2013086024A3 (en) | Dermal filler compositions | |
AU337887S (en) | Allsaw | |
MX2014016121A (es) | Agente para prevenir el deterioro de la funcion endotelial vascular o para mejorar la funcion endotelial vascular. | |
EP2575452A4 (en) | ANTIMICROBIAL COMPOSITIONS | |
PH12014502858A1 (en) | Racecadotril lipid compositions | |
MX2015003711A (es) | Metodos y composiciones para extender la vida útil en déposito de productos de plantas. | |
MX2017000437A (es) | Ensamble de pesca de liberacion rapida. | |
TN2013000201A1 (en) | Methods and compositions for drying coal | |
PH12015501390A1 (en) | Tablets with improved acceptance and good storage stability | |
UY33656A (es) | Composición aceleradora para elastómeros | |
IN2014MN02257A (es) | ||
EP2902480A4 (en) | PAECILOMYCES VARIOTII VAR. BRUNNEOLUS GPP1101B AND PROCESS FOR PREPARING THE SAME | |
AU337888S (en) | Allsaw | |
MX2015002908A (es) | Polipeptido con actividad reforzada de beta-glucosidasa a baja temperatura. | |
AU2024204415A1 (en) | Lactase enzymes with improved activity at low temperatures | |
MX366768B (es) | Tableta orodispersable de sildenafil y metodo para preparar la misma. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |